TRK fusions - Revision history

Michael: +image

2023-10-18T20:04:21Z

+image

← Older revision		Revision as of 20:04, 18 October 2023
Line 1:		Line 1:
			[[Image: Mammary analogue secretory carcinoma (H&E, medium power).jpg \| thumb \| [[Secretory carcinoma of the salivary gland]] is a tumour that is characterized by TRK fusions. [[H&E stain]]. (WC/NormanDy)]]
	'''TRK fusions''' are seen in many solid tumours of children and adults and have targeted drugs.<ref name=pmid29466156>{{Cite journal \| last1 = Drilon \| first1 = A. \| last2 = Laetsch \| first2 = TW. \| last3 = Kummar \| first3 = S. \| last4 = DuBois \| first4 = SG. \| last5 = Lassen \| first5 = UN. \| last6 = Demetri \| first6 = GD. \| last7 = Nathenson \| first7 = M. \| last8 = Doebele \| first8 = RC. \| last9 = Farago \| first9 = AF. \| title = Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. \| journal = N Engl J Med \| volume = 378 \| issue = 8 \| pages = 731-739 \| month = 02 \| year = 2018 \| doi = 10.1056/NEJMoa1714448 \| PMID = 29466156 }}</ref>		'''TRK fusions''' are seen in many solid tumours of children and adults and have targeted drugs.<ref name=pmid29466156>{{Cite journal \| last1 = Drilon \| first1 = A. \| last2 = Laetsch \| first2 = TW. \| last3 = Kummar \| first3 = S. \| last4 = DuBois \| first4 = SG. \| last5 = Lassen \| first5 = UN. \| last6 = Demetri \| first6 = GD. \| last7 = Nathenson \| first7 = M. \| last8 = Doebele \| first8 = RC. \| last9 = Farago \| first9 = AF. \| title = Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. \| journal = N Engl J Med \| volume = 378 \| issue = 8 \| pages = 731-739 \| month = 02 \| year = 2018 \| doi = 10.1056/NEJMoa1714448 \| PMID = 29466156 }}</ref>

Michael at 19:40, 11 October 2023

2023-10-11T19:40:21Z

← Older revision		Revision as of 19:40, 11 October 2023
Line 12:		Line 12:

	Testing:		Testing:
	*RNA-based next generation sequencing.		*RNA-based [[next generation sequencing]].
	*[[Immunohistochemistry]]<ref name=pmid28719467>{{Cite journal \| last1 = Hechtman \| first1 = JF. \| last2 = Benayed \| first2 = R. \| last3 = Hyman \| first3 = DM. \| last4 = Drilon \| first4 = A. \| last5 = Zehir \| first5 = A. \| last6 = Frosina \| first6 = D. \| last7 = Arcila \| first7 = ME. \| last8 = Dogan \| first8 = S. \| last9 = Klimstra \| first9 = DS. \| title = Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions. \| journal = Am J Surg Pathol \| volume = 41 \| issue = 11 \| pages = 1547-1551 \| month = Nov \| year = 2017 \| doi = 10.1097/PAS.0000000000000911 \| PMID = 28719467 }}</ref> - limited sensitivity for leiomyosarcoma, neural differentiation tumours.		*[[Immunohistochemistry]]<ref name=pmid28719467>{{Cite journal \| last1 = Hechtman \| first1 = JF. \| last2 = Benayed \| first2 = R. \| last3 = Hyman \| first3 = DM. \| last4 = Drilon \| first4 = A. \| last5 = Zehir \| first5 = A. \| last6 = Frosina \| first6 = D. \| last7 = Arcila \| first7 = ME. \| last8 = Dogan \| first8 = S. \| last9 = Klimstra \| first9 = DS. \| title = Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions. \| journal = Am J Surg Pathol \| volume = 41 \| issue = 11 \| pages = 1547-1551 \| month = Nov \| year = 2017 \| doi = 10.1097/PAS.0000000000000911 \| PMID = 28719467 }}</ref> - limited sensitivity for leiomyosarcoma, neural differentiation tumours.
	*FISH breakapart probes.		*FISH breakapart probes.

Michael: vauthors

2020-05-24T20:29:26Z

vauthors

← Older revision		Revision as of 20:29, 24 May 2020
Line 2:		Line 2:

	==General==		==General==
	Genes:<ref name=pmid27843590>{{cite journal \|~~vauthors~~=Amatu A, Sartore-Bianchi A, Siena S \|title=NTRK gene fusions as novel targets of cancer therapy across multiple tumour types \|journal=ESMO Open \|volume=1 \|issue=2 \|pages=e000023 \|date=2016 \|pmid=27843590 \|pmc=5070277 \|doi=10.1136/esmoopen-2015-000023 \|url=https://www.ncbi.nlm.nih.gov/pubmed/27843590}}</ref>		Genes:<ref name=pmid27843590>{{cite journal \|authors=Amatu A, Sartore-Bianchi A, Siena S \|title=NTRK gene fusions as novel targets of cancer therapy across multiple tumour types \|journal=ESMO Open \|volume=1 \|issue=2 \|pages=e000023 \|date=2016 \|pmid=27843590 \|pmc=5070277 \|doi=10.1136/esmoopen-2015-000023 \|url=https://www.ncbi.nlm.nih.gov/pubmed/27843590}}</ref>
	*NTRK1.		*NTRK1.
	*NTRK2.		*NTRK2.

Michael: /* Classic */

2019-12-31T15:28:26Z

Classic

← Older revision		Revision as of 15:28, 31 December 2019
Line 21:		Line 21:
	===Classic===		===Classic===

	*[[~~Mammary analogue secretory~~ carcinoma]] (~~MASC~~) - ETV6-NTRK3.<ref name=pmid22127547>{{Cite journal \| last1 = Lei \| first1 = Y. \| last2 = Chiosea \| first2 = SI. \| title = Re-evaluating historic cohort of salivary acinic cell carcinoma with new diagnostic tools. \| journal = Head Neck Pathol \| volume = 6 \| issue = 2 \| pages = 166-70 \| month = Jun \| year = 2012 \| doi = 10.1007/s12105-011-0312-9 \| PMID = 22127547 }}</ref>		*[[Secretory carcinoma of the salivary gland]] (previously ''mammary analogue secretory carcinoma'') - ETV6-NTRK3.<ref name=pmid22127547>{{Cite journal \| last1 = Lei \| first1 = Y. \| last2 = Chiosea \| first2 = SI. \| title = Re-evaluating historic cohort of salivary acinic cell carcinoma with new diagnostic tools. \| journal = Head Neck Pathol \| volume = 6 \| issue = 2 \| pages = 166-70 \| month = Jun \| year = 2012 \| doi = 10.1007/s12105-011-0312-9 \| PMID = 22127547 }}</ref>
	*[[Secretory breast carcinoma]] - ETV6-NTRK3.<ref name=pmid22129193>{{Cite journal \| last1 = Vasudev \| first1 = P. \| last2 = Onuma \| first2 = K. \| title = Secretory breast carcinoma: unique, triple-negative carcinoma with a favorable prognosis and characteristic molecular expression. \| journal = Arch Pathol Lab Med \| volume = 135 \| issue = 12 \| pages = 1606-10 \| month = Dec \| year = 2011 \| doi = 10.5858/arpa.2010-0351-RS \| PMID = 22129193 }}</ref>		*[[Secretory breast carcinoma]] - ETV6-NTRK3.<ref name=pmid22129193>{{Cite journal \| last1 = Vasudev \| first1 = P. \| last2 = Onuma \| first2 = K. \| title = Secretory breast carcinoma: unique, triple-negative carcinoma with a favorable prognosis and characteristic molecular expression. \| journal = Arch Pathol Lab Med \| volume = 135 \| issue = 12 \| pages = 1606-10 \| month = Dec \| year = 2011 \| doi = 10.5858/arpa.2010-0351-RS \| PMID = 22129193 }}</ref>

	===Others===		===Others===
	*[[Congenital-infantile fibrosarcoma]].<ref name=pmid11242790 >{{Cite journal \| last1 = Sheng \| first1 = WQ. \| last2 = Hisaoka \| first2 = M. \| last3 = Okamoto \| first3 = S. \| last4 = Tanaka \| first4 = A. \| last5 = Meis-Kindblom \| first5 = JM. \| last6 = Kindblom \| first6 = LG. \| last7 = Ishida \| first7 = T. \| last8 = Nojima \| first8 = T. \| last9 = Hashimoto \| first9 = H. \| title = Congenital-infantile fibrosarcoma. A clinicopathologic study of 10 cases and molecular detection of the ETV6-NTRK3 fusion transcripts using paraffin-embedded tissues. \| journal = Am J Clin Pathol \| volume = 115 \| issue = 3 \| pages = 348-55 \| month = Mar \| year = 2001 \| doi = 10.1309/3H24-E7T7-V37G-AKKQ \| PMID = 11242790 }}</ref>		*[[Congenital-infantile fibrosarcoma]].<ref name=pmid11242790 >{{Cite journal \| last1 = Sheng \| first1 = WQ. \| last2 = Hisaoka \| first2 = M. \| last3 = Okamoto \| first3 = S. \| last4 = Tanaka \| first4 = A. \| last5 = Meis-Kindblom \| first5 = JM. \| last6 = Kindblom \| first6 = LG. \| last7 = Ishida \| first7 = T. \| last8 = Nojima \| first8 = T. \| last9 = Hashimoto \| first9 = H. \| title = Congenital-infantile fibrosarcoma. A clinicopathologic study of 10 cases and molecular detection of the ETV6-NTRK3 fusion transcripts using paraffin-embedded tissues. \| journal = Am J Clin Pathol \| volume = 115 \| issue = 3 \| pages = 348-55 \| month = Mar \| year = 2001 \| doi = 10.1309/3H24-E7T7-V37G-AKKQ \| PMID = 11242790 }}</ref>

Michael: /* General */

2019-03-19T11:37:18Z

General

← Older revision		Revision as of 11:37, 19 March 2019
Line 13:		Line 13:
	Testing:		Testing:
	*RNA-based next generation sequencing.		*RNA-based next generation sequencing.
	*[[Immunohistochemistry]]<ref name=pmid28719467>{{Cite journal \| last1 = Hechtman \| first1 = JF. \| last2 = Benayed \| first2 = R. \| last3 = Hyman \| first3 = DM. \| last4 = Drilon \| first4 = A. \| last5 = Zehir \| first5 = A. \| last6 = Frosina \| first6 = D. \| last7 = Arcila \| first7 = ME. \| last8 = Dogan \| first8 = S. \| last9 = Klimstra \| first9 = DS. \| title = Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions. \| journal = Am J Surg Pathol \| volume = 41 \| issue = 11 \| pages = 1547-1551 \| month = Nov \| year = 2017 \| doi = 10.1097/PAS.0000000000000911 \| PMID = 28719467 }}</ref> - limited sensitivity for leiomyosarcoma ~~+ others~~ tumours.		*[[Immunohistochemistry]]<ref name=pmid28719467>{{Cite journal \| last1 = Hechtman \| first1 = JF. \| last2 = Benayed \| first2 = R. \| last3 = Hyman \| first3 = DM. \| last4 = Drilon \| first4 = A. \| last5 = Zehir \| first5 = A. \| last6 = Frosina \| first6 = D. \| last7 = Arcila \| first7 = ME. \| last8 = Dogan \| first8 = S. \| last9 = Klimstra \| first9 = DS. \| title = Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions. \| journal = Am J Surg Pathol \| volume = 41 \| issue = 11 \| pages = 1547-1551 \| month = Nov \| year = 2017 \| doi = 10.1097/PAS.0000000000000911 \| PMID = 28719467 }}</ref> - limited sensitivity for leiomyosarcoma, neural differentiation tumours.
	*FISH breakapart probes.		*FISH breakapart probes.
	*DNA NGS<ref>{{Cite journal \| last1 = Cocco \| first1 = E. \| last2 = Scaltriti \| first2 = M. \| last3 = Drilon \| first3 = A. \| title = NTRK fusion-positive cancers and TRK inhibitor therapy. \| journal = Nat Rev Clin Oncol \| volume = 15 \| issue = 12 \| pages = 731-747 \| month = Dec \| year = 2018 \| doi = 10.1038/s41571-018-0113-0 \| PMID = 30333516 }}		*DNA NGS<ref>{{Cite journal \| last1 = Cocco \| first1 = E. \| last2 = Scaltriti \| first2 = M. \| last3 = Drilon \| first3 = A. \| title = NTRK fusion-positive cancers and TRK inhibitor therapy. \| journal = Nat Rev Clin Oncol \| volume = 15 \| issue = 12 \| pages = 731-747 \| month = Dec \| year = 2018 \| doi = 10.1038/s41571-018-0113-0 \| PMID = 30333516 }}

Michael at 11:36, 19 March 2019

2019-03-19T11:36:25Z

← Older revision		Revision as of 11:36, 19 March 2019
Line 13:		Line 13:
	Testing:		Testing:
	*RNA-based next generation sequencing.		*RNA-based next generation sequencing.
	*[[Immunohistochemistry]]<ref name=pmid28719467>{{Cite journal \| last1 = Hechtman \| first1 = JF. \| last2 = Benayed \| first2 = R. \| last3 = Hyman \| first3 = DM. \| last4 = Drilon \| first4 = A. \| last5 = Zehir \| first5 = A. \| last6 = Frosina \| first6 = D. \| last7 = Arcila \| first7 = ME. \| last8 = Dogan \| first8 = S. \| last9 = Klimstra \| first9 = DS. \| title = Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions. \| journal = Am J Surg Pathol \| volume = 41 \| issue = 11 \| pages = 1547-1551 \| month = Nov \| year = 2017 \| doi = 10.1097/PAS.0000000000000911 \| PMID = 28719467 }}</ref> - limited sensitivity?		*[[Immunohistochemistry]]<ref name=pmid28719467>{{Cite journal \| last1 = Hechtman \| first1 = JF. \| last2 = Benayed \| first2 = R. \| last3 = Hyman \| first3 = DM. \| last4 = Drilon \| first4 = A. \| last5 = Zehir \| first5 = A. \| last6 = Frosina \| first6 = D. \| last7 = Arcila \| first7 = ME. \| last8 = Dogan \| first8 = S. \| last9 = Klimstra \| first9 = DS. \| title = Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions. \| journal = Am J Surg Pathol \| volume = 41 \| issue = 11 \| pages = 1547-1551 \| month = Nov \| year = 2017 \| doi = 10.1097/PAS.0000000000000911 \| PMID = 28719467 }}</ref> - limited sensitivity for leiomyosarcoma + others tumours.
	*FISH breakapart probes.		*FISH breakapart probes.
	*DNA NGS<ref>{{Cite journal \| last1 = Cocco \| first1 = E. \| last2 = Scaltriti \| first2 = M. \| last3 = Drilon \| first3 = A. \| title = NTRK fusion-positive cancers and TRK inhibitor therapy. \| journal = Nat Rev Clin Oncol \| volume = 15 \| issue = 12 \| pages = 731-747 \| month = Dec \| year = 2018 \| doi = 10.1038/s41571-018-0113-0 \| PMID = 30333516 }}		*DNA NGS<ref>{{Cite journal \| last1 = Cocco \| first1 = E. \| last2 = Scaltriti \| first2 = M. \| last3 = Drilon \| first3 = A. \| title = NTRK fusion-positive cancers and TRK inhibitor therapy. \| journal = Nat Rev Clin Oncol \| volume = 15 \| issue = 12 \| pages = 731-747 \| month = Dec \| year = 2018 \| doi = 10.1038/s41571-018-0113-0 \| PMID = 30333516 }}

Michael: /* General */

2019-03-19T11:30:53Z

General

← Older revision		Revision as of 11:30, 19 March 2019
Line 14:		Line 14:
	*RNA-based next generation sequencing.		*RNA-based next generation sequencing.
	*[[Immunohistochemistry]]<ref name=pmid28719467>{{Cite journal \| last1 = Hechtman \| first1 = JF. \| last2 = Benayed \| first2 = R. \| last3 = Hyman \| first3 = DM. \| last4 = Drilon \| first4 = A. \| last5 = Zehir \| first5 = A. \| last6 = Frosina \| first6 = D. \| last7 = Arcila \| first7 = ME. \| last8 = Dogan \| first8 = S. \| last9 = Klimstra \| first9 = DS. \| title = Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions. \| journal = Am J Surg Pathol \| volume = 41 \| issue = 11 \| pages = 1547-1551 \| month = Nov \| year = 2017 \| doi = 10.1097/PAS.0000000000000911 \| PMID = 28719467 }}</ref> - limited sensitivity?		*[[Immunohistochemistry]]<ref name=pmid28719467>{{Cite journal \| last1 = Hechtman \| first1 = JF. \| last2 = Benayed \| first2 = R. \| last3 = Hyman \| first3 = DM. \| last4 = Drilon \| first4 = A. \| last5 = Zehir \| first5 = A. \| last6 = Frosina \| first6 = D. \| last7 = Arcila \| first7 = ME. \| last8 = Dogan \| first8 = S. \| last9 = Klimstra \| first9 = DS. \| title = Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions. \| journal = Am J Surg Pathol \| volume = 41 \| issue = 11 \| pages = 1547-1551 \| month = Nov \| year = 2017 \| doi = 10.1097/PAS.0000000000000911 \| PMID = 28719467 }}</ref> - limited sensitivity?
			*FISH breakapart probes.
			*DNA NGS<ref>{{Cite journal \| last1 = Cocco \| first1 = E. \| last2 = Scaltriti \| first2 = M. \| last3 = Drilon \| first3 = A. \| title = NTRK fusion-positive cancers and TRK inhibitor therapy. \| journal = Nat Rev Clin Oncol \| volume = 15 \| issue = 12 \| pages = 731-747 \| month = Dec \| year = 2018 \| doi = 10.1038/s41571-018-0113-0 \| PMID = 30333516 }}
			</ref> - sensitivity low for fusions.

	==Associations==		==Associations==

Michael: /* Associations */

2019-03-19T10:30:50Z

Associations

← Older revision		Revision as of 10:30, 19 March 2019
Line 24:		Line 24:
	*Cellular [[mesoblastic nephroma]].<ref name=pmid29893456>{{Cite journal \| last1 = Halalsheh \| first1 = H. \| last2 = McCarville \| first2 = MB. \| last3 = Neel \| first3 = M. \| last4 = Reynolds \| first4 = M. \| last5 = Cox \| first5 = MC. \| last6 = Pappo \| first6 = AS. \| title = Dramatic bone remodeling following larotrectinib administration for bone metastasis in a patient with TRK fusion congenital mesoblastic nephroma. \| journal = Pediatr Blood Cancer \| volume = 65 \| issue = 10 \| pages = e27271 \| month = Oct \| year = 2018 \| doi = 10.1002/pbc.27271 \| PMID = 29893456 }}</ref><ref name=pmid29683818>{{Cite journal \| last1 = Rudzinski \| first1 = ER. \| last2 = Lockwood \| first2 = CM. \| last3 = Stohr \| first3 = BA. \| last4 = Vargas \| first4 = SO. \| last5 = Sheridan \| first5 = R. \| last6 = Black \| first6 = JO. \| last7 = Rajaram \| first7 = V. \| last8 = Laetsch \| first8 = TW. \| last9 = Davis \| first9 = JL. \| title = Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors. \| journal = Am J Surg Pathol \| volume = 42 \| issue = 7 \| pages = 927-935 \| month = Jul \| year = 2018 \| doi = 10.1097/PAS.0000000000001062 \| PMID = 29683818 }}</ref>		*Cellular [[mesoblastic nephroma]].<ref name=pmid29893456>{{Cite journal \| last1 = Halalsheh \| first1 = H. \| last2 = McCarville \| first2 = MB. \| last3 = Neel \| first3 = M. \| last4 = Reynolds \| first4 = M. \| last5 = Cox \| first5 = MC. \| last6 = Pappo \| first6 = AS. \| title = Dramatic bone remodeling following larotrectinib administration for bone metastasis in a patient with TRK fusion congenital mesoblastic nephroma. \| journal = Pediatr Blood Cancer \| volume = 65 \| issue = 10 \| pages = e27271 \| month = Oct \| year = 2018 \| doi = 10.1002/pbc.27271 \| PMID = 29893456 }}</ref><ref name=pmid29683818>{{Cite journal \| last1 = Rudzinski \| first1 = ER. \| last2 = Lockwood \| first2 = CM. \| last3 = Stohr \| first3 = BA. \| last4 = Vargas \| first4 = SO. \| last5 = Sheridan \| first5 = R. \| last6 = Black \| first6 = JO. \| last7 = Rajaram \| first7 = V. \| last8 = Laetsch \| first8 = TW. \| last9 = Davis \| first9 = JL. \| title = Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors. \| journal = Am J Surg Pathol \| volume = 42 \| issue = 7 \| pages = 927-935 \| month = Jul \| year = 2018 \| doi = 10.1097/PAS.0000000000001062 \| PMID = 29683818 }}</ref>
	*NTRK1 fusions occasionally in [[Glioblastoma]] (1-2%).<ref>{{Cite journal \| last1 = Xu \| first1 = T. \| last2 = Wang \| first2 = H. \| last3 = Huang \| first3 = X. \| last4 = Li \| first4 = W. \| last5 = Huang \| first5 = Q. \| last6 = Yan \| first6 = Y. \| last7 = Chen \| first7 = J. \| title = Gene Fusion in Malignant Glioma: An Emerging Target for Next-Generation Personalized Treatment. \| journal = Transl Oncol \| volume = 11 \| issue = 3 \| pages = 609-618 \| month = Jun \| year = 2018 \| doi = 10.1016/j.tranon.2018.02.020 \| PMID = 29571074 }}</ref>		*NTRK1 fusions occasionally in [[Glioblastoma]] (1-2%).<ref>{{Cite journal \| last1 = Xu \| first1 = T. \| last2 = Wang \| first2 = H. \| last3 = Huang \| first3 = X. \| last4 = Li \| first4 = W. \| last5 = Huang \| first5 = Q. \| last6 = Yan \| first6 = Y. \| last7 = Chen \| first7 = J. \| title = Gene Fusion in Malignant Glioma: An Emerging Target for Next-Generation Personalized Treatment. \| journal = Transl Oncol \| volume = 11 \| issue = 3 \| pages = 609-618 \| month = Jun \| year = 2018 \| doi = 10.1016/j.tranon.2018.02.020 \| PMID = 29571074 }}</ref>
			*SQSTM1-NTRK1 non-small cell carcinoma (~0.1%).<ref>{{Cite journal \| last1 = Agaimy \| first1 = A. \| last2 = Hartmann \| first2 = A. \| last3 = Antonescu \| first3 = CR. \| last4 = Chiosea \| first4 = SI. \| last5 = El-Mofty \| first5 = SK. \| last6 = Geddert \| first6 = H. \| last7 = Iro \| first7 = H. \| last8 = Lewis \| first8 = JS. \| last9 = Märkl \| first9 = B. \| title = SMARCB1 (INI-1)-deficient Sinonasal Carcinoma: A Series of 39 Cases Expanding the Morphologic and Clinicopathologic Spectrum of a Recently Described Entity. \| journal = Am J Surg Pathol \| volume = 41 \| issue = 4 \| pages = 458-471 \| month = Apr \| year = 2017 \| doi = 10.1097/PAS.0000000000000797 \| PMID = 28291122 }}</ref>

	==Drugs==		==Drugs==

Michael: /* Drugs */

2019-03-19T10:29:45Z

Drugs

← Older revision		Revision as of 10:29, 19 March 2019
Line 28:		Line 28:
	*Merestinib.		*Merestinib.
	*Larotrectinib.<ref name=pmid29466156>{{Cite journal \| last1 = Drilon \| first1 = A. \| last2 = Laetsch \| first2 = TW. \| last3 = Kummar \| first3 = S. \| last4 = DuBois \| first4 = SG. \| last5 = Lassen \| first5 = UN. \| last6 = Demetri \| first6 = GD. \| last7 = Nathenson \| first7 = M. \| last8 = Doebele \| first8 = RC. \| last9 = Farago \| first9 = AF. \| title = Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. \| journal = N Engl J Med \| volume = 378 \| issue = 8 \| pages = 731-739 \| month = 02 \| year = 2018 \| doi = 10.1056/NEJMoa1714448 \| PMID = 29466156 }}</ref>		*Larotrectinib.<ref name=pmid29466156>{{Cite journal \| last1 = Drilon \| first1 = A. \| last2 = Laetsch \| first2 = TW. \| last3 = Kummar \| first3 = S. \| last4 = DuBois \| first4 = SG. \| last5 = Lassen \| first5 = UN. \| last6 = Demetri \| first6 = GD. \| last7 = Nathenson \| first7 = M. \| last8 = Doebele \| first8 = RC. \| last9 = Farago \| first9 = AF. \| title = Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. \| journal = N Engl J Med \| volume = 378 \| issue = 8 \| pages = 731-739 \| month = 02 \| year = 2018 \| doi = 10.1056/NEJMoa1714448 \| PMID = 29466156 }}</ref>
			*Entrectinib.<ref name=pmid26565381>{{Cite journal \| last1 = Farago \| first1 = AF. \| last2 = Le \| first2 = LP. \| last3 = Zheng \| first3 = Z. \| last4 = Muzikansky \| first4 = A. \| last5 = Drilon \| first5 = A. \| last6 = Patel \| first6 = M. \| last7 = Bauer \| first7 = TM. \| last8 = Liu \| first8 = SV. \| last9 = Ou \| first9 = SH. \| title = Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer. \| journal = J Thorac Oncol \| volume = 10 \| issue = 12 \| pages = 1670-4 \| month = Dec \| year = 2015 \| doi = 10.1097/01.JTO.0000473485.38553.f0 \| PMID = 26565381 }}</ref>
	*Others.		*Others.

Michael: /* Associations */

2018-10-26T15:04:42Z

Associations

← Older revision		Revision as of 15:04, 26 October 2018
Line 18:		Line 18:
	===Classic===		===Classic===

	*[[Mammary analogue secretory carcinoma]] (MASC) - ''ETV6-NTRK3.<ref name=pmid22127547>{{Cite journal \| last1 = Lei \| first1 = Y. \| last2 = Chiosea \| first2 = SI. \| title = Re-evaluating historic cohort of salivary acinic cell carcinoma with new diagnostic tools. \| journal = Head Neck Pathol \| volume = 6 \| issue = 2 \| pages = 166-70 \| month = Jun \| year = 2012 \| doi = 10.1007/s12105-011-0312-9 \| PMID = 22127547 }}</ref>		*[[Mammary analogue secretory carcinoma]] (MASC) - ETV6-NTRK3.<ref name=pmid22127547>{{Cite journal \| last1 = Lei \| first1 = Y. \| last2 = Chiosea \| first2 = SI. \| title = Re-evaluating historic cohort of salivary acinic cell carcinoma with new diagnostic tools. \| journal = Head Neck Pathol \| volume = 6 \| issue = 2 \| pages = 166-70 \| month = Jun \| year = 2012 \| doi = 10.1007/s12105-011-0312-9 \| PMID = 22127547 }}</ref>
	*[[Secretory breast carcinoma]] - ETV6-NTRK3.<ref name=pmid22129193>{{Cite journal \| last1 = Vasudev \| first1 = P. \| last2 = Onuma \| first2 = K. \| title = Secretory breast carcinoma: unique, triple-negative carcinoma with a favorable prognosis and characteristic molecular expression. \| journal = Arch Pathol Lab Med \| volume = 135 \| issue = 12 \| pages = 1606-10 \| month = Dec \| year = 2011 \| doi = 10.5858/arpa.2010-0351-RS \| PMID = 22129193 }}</ref>		*[[Secretory breast carcinoma]] - ETV6-NTRK3.<ref name=pmid22129193>{{Cite journal \| last1 = Vasudev \| first1 = P. \| last2 = Onuma \| first2 = K. \| title = Secretory breast carcinoma: unique, triple-negative carcinoma with a favorable prognosis and characteristic molecular expression. \| journal = Arch Pathol Lab Med \| volume = 135 \| issue = 12 \| pages = 1606-10 \| month = Dec \| year = 2011 \| doi = 10.5858/arpa.2010-0351-RS \| PMID = 22129193 }}</ref>
	===Others===		===Others===